Ra Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Net loss
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Non-cash operating lease expense
Stock-based compensation
Other non-cash operating activities
Change in fair value of preferred stock tranche rights
Series B-2 Preferred Stock
Total change in fair value of preferred stock tranche rights
Other, net
Changes in operating assets and liabilities:
Other non-current assets
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Deferred rent and other non current liabilities
Operating lease liabilities
Deferred rent
Deferred revenue
Other, net

Net cash used in operating activities

Cash flows from investing activities
Purchase of property and equipment
Proceeds from sale of property and equipment
Decrease (increase) in restricted cash
Other, net
Net cash used in investing activities

Cash flows from financing activities
Proceeds from common stock offerings, net of underwriter discounts
Proceeds from common stock offering, net of underwriter discounts
Payment of common stock offering costs
Payment of preferred stock issuance costs
Proceeds from disgorgement of stockholder's short-swing profits
Payments related to restricted stock units vesting
Proceeds from exercises of stock options and ESPP shares
Net increase in cash and cash equivalents
Cash and cash equivalents
Other, net
Net cash provided by financing activities

Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Noncash operating activity:
Operating lease liabilities arising from obtaining right-of-use assets
Noncash investing and financing activity:
Common stock offering costs incurred but unpaid at period end
Changes in liabilities and prepaid expenses related to fixed asset additions
Supplemental cash flow information:
Conversion of redeemable convertible preferred stock into common stock
Series B-2 Preferred Stock
Series B-1 Preferred Stock
Series A Preferred Stock
Total conversion of redeemable convertible preferred stock into common stock
Reclassification of Series B-2 tranche right liability to the balance of Series B-2 redeemable convertible preferred stock
Cash and cash equivalents
Restricted cash

Comments